Method for the treatment of Dravet syndrome
View Patent ↗A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
1. A method of stimulating 5-HT receptors in the brain of a patient diagnosed with Dravet syndrome, comprising:
administering to the patient 0.2 mg/kg/day of fenfluramine or a pharmaceutically acceptable salt thereof; and
administering to the patient an effective dose of stiripentol or a pharmaceutically acceptable salt thereof;
whereby 5-HT receptors are stimulated and wherein the 5-HT receptor is in a family of receptors selected from the group consisting of 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7.
2. The method of claim 1 , wherein the 5-HT receptor is in the 5-HT1 receptor family and is selected from the group consisting of 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, 5-HT1E, 5-HT1F.
3. The method of claim 1 , wherein the 5-HT receptor is in the 5-HT2 receptor family and is selected from the group consisting of 5-HT2A, 5-HT2B, 5-HT2C.
4. The method of claim 1 , wherein the 5-HT receptor is the 5-HT3 receptor.
5. A method of stimulating 5-HT receptors in the brain of a patient diagnosed with Dravet syndrome, comprising:
administering to the patient an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof administered in a dose of 0.5 mg/kg/day to 0.2 mg/kg/day to the patient; and
administering to the patient an effective dose of stiripentol or a pharmaceutically acceptable salt thereof;
whereby 5-HT receptors are stimulated.
6. The method of claim 5 , wherein the effective dose is administered in the form of one or more dosage forms for oral, injectable, transdermal, inhaled, nasal, rectal, vaginal or parenteral delivery.